At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the results of the randomised, double-blind, phase 2 TERRAIN trial, which compared enzalutamide, a novel androgen receptor signalling inhibitor, with bicalutamide, a non-steroidal antiandrogen, for men with metastatic castrate-resistant prostate cancer.
TERRAIN trial of enzalutamide versus bicalutamide for advanced prostate cancer
14th October 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now